The UK’s National Institute for Health and Care Excellence (NICE) announced on Thursday that it plans to recommend Eli Lilly’s obesity drug Mounjaro for use through the National Health Service (NHS), potentially benefiting 220,000 patients over the next three years.
Previously available in the UK only through private, out-of-pocket purchases, Mounjaro, launched in February 2023, will now be prescribed alongside lifestyle changes like diet and exercise. The eligibility criteria include individuals with a body mass index (BMI) over 35 and at least one weight-related condition such as heart disease or type 2 diabetes.
Phased Rollout and Eligibility
Approximately 3.4 million people in England could qualify for the treatment under the stated guidelines. However, during the initial rollout, priority will be given to those with the highest clinical need. The drug will become accessible to NHS patients starting 90 days after NICE’s final guidance is published, scheduled for December 23, unless appeals are lodged. Patients who are part of specialist NHS weight management services will gain earlier access, while others may need to wait up to 180 days.
The phased rollout is essential to ensure that healthcare providers can continue addressing the broader range of patient needs, NICE stated.
Mounjaro’s Potential Impact
Mounjaro, part of the GLP-1 analogue drug class, was initially developed to manage blood sugar levels in type 2 diabetes patients but has shown remarkable efficacy in promoting weight loss. Clinical trials demonstrated an average weight loss of nearly 23%, making it one of the most effective options for obesity management.
This recommendation aligns with earlier guidelines issued by NICE for Novo Nordisk’s Wegovy in March 2023, which targets the same BMI threshold and weight-related conditions.
Addressing Britain’s Obesity Crisis
With nearly one in three adults in Britain classified as obese—the highest rate in Europe according to a 2019 OECD report—Mounjaro offers a new tool to address the nation’s obesity epidemic. The European Union’s obesity average stands at 16.5%, highlighting the urgent need for interventions in the UK.
Eli Lilly has welcomed NICE’s decision and acknowledged the necessity of a phased introduction, ensuring the drug is integrated effectively into the NHS system.